Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 15.79 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $9.89 million which beat the analyst consensus estimate of $4.07 million by 143.13 percent.